Molecular determinants of drug-receptor binding kinetics

Drug Discovery Today

Volumn 18, Issue 13-14, 2013, Pages 667-673

  Pan, Albert C ^a   Borhani, David W ^a   Dror, Ron O ^a   Shaw, David E ^a,b  

^a D E SHAW RESEARCH   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WATER;

BINDING AFFINITY; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG RECEPTOR BINDING; HYDROPHOBICITY; KINETICS; MOLECULAR SIZE; REVIEW; STATIC ELECTRICITY;

ANIMALS; BINDING SITES; DRUG DESIGN; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84879925936     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.02.007     Document Type: Review

References (59)

1. J.N. Langley On the reaction of cells and of nerve-endings to certain poisons, cheifly as regards the reaction of striated muscle to nicotine and to curari J. Physiol. 33 1905 374 413
2. R.A. Copeland Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discov. 5 2006 730 739
3. D.C. Swinney The role of binding kinetics in therapeutically useful drug action Curr. Opin. Drug Discov. Dev. 12 2009 31 39
4. H. Lu, and P.J. Tonge Drug-target residence time: critical information for lead optimization Curr. Opin. Chem. Biol. 14 2010 467 474
5. 2A receptor agonists is positively correlated to their receptor residence time Br. J. Pharmacol. 166 2012 1846 1859
6. S.A. Lipton Turning down, but not off: neuroprotection requires a paradigm shift in drug development Nature 428 2004 473
7. S. Ohlson Designing transient binding drugs: a new concept for drug discovery Drug Discov. Today 13 2008 433 439
8. G. Vauquelin Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism Naunyn-Schmiedeberg's Arch. Pharmacol. 385 2012 337 372
9. W. Keighley The need for high throughput kinetics early in the drug discovery process Drug Disc. World Summer 2011 2011 39 45
10. D.C. Miller Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target Med. Chem. Commun. 3 2012 449 452
11. B.A. Fleck Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor J. Pharmacol. Exp. Ther. 341 2012 518 531
12. H. Frauenfelder The energy landscapes and motions of proteins Science 254 1991 1598 1603
13. T. Uchida Effects of the intramolecular disulfide bond on ligand binding dynamics in myoglobin Biochemistry 36 1997 324 332
14. S.R. Luckner A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis J. Biol. Chem. 285 2010 14330 14337
15. A.C. Kruse Structure and dynamics of the M3 muscarinic acetylcholine receptor Nature 482 2012 552 556
16. C. Pargellis Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat. Struct. Biol. 9 2002 268 272
17. D.S. Millan Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease J. Med. Chem. 52 2011 7797 7814
18. B.J. Barnes The pharmacological properties of tiotropium Chest 117 Suppl. 2 2000 63 66
19. D.A. Sykes The influence of receptor kinetics on the onset and duration of action, and the therapeutic index of NVA237 and tiotropium J. Pharmacol. Exp. Ther. 343 2012 520 528
20. R.A. Robinson, and R.H. Stokes Electrolyte Solutions 2nd edn 2002 Butterworth & Co.
21. S.F. Sun Physical Chemistry of Macromolecules 2004 John Wiley and Sons, Inc.
22. G. Schreiber, and A.R. Fersht Rapid, electrostatically assisted association of proteins Nat. Struct. Biol. 3 1996 427 431
23. N.U. Fedosova Nucleotide binding to Na, K-ATPase: the role of electrostatic interactions Biochemistry 41 2002 1267 1273
24. Z. Radić Electrostatic influence on the kinetics of ligand binding to acetylcholinesterase. Distinctions between active center ligands and fasciculin J. Biol. Chem. 272 1997 23265 23277
25. K.D. Collins Why continuum electrostatics theories cannot explain biological structure, polyelectrolytes or ionic strength effects in ion-protein interactions Biophys. Chem. 167 2012 43 59
26. P.S. Ledvina Dominant role of local dipolar interactions in phosphate binding to a receptor cleft with an electronegative charge surface: equilibrium, kinetic, and crystallographic studies Protein Sci. 7 1998 2550 2559
27. V.M. Krishnamurthy Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding Chem. Rev. 103 2008 946 1051
28. H.-J. Böhm, and G. Klebe What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew. Chem. Int. Ed. Engl. 3S 1996 2588 2614
29. T. Uchida The effects of heme pocket hydrophobicity on the ligand binding dynamics in myoglobin as studied with leucine 29 mutants J. Biol. Chem. 272 1997 30108 30114
30. P. Setny Solvent fluctuations in hydrophobic cavity-ligand binding kinetics Proc. Natl. Acad. Sci. U. S. A. 110 2013 1197 1202
31. M. Ahmad Mechanism of fast peptide recognition by SH3 domains Angew. Chem. Int. Ed. Engl. 47 2008 7626 7630
32. P. Setny Dewetting-controlled binding of ligands to hydrophobic pockets Phys. Rev. Lett. 103 2009 187801
33. S. Han Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa Proc. Natl. Acad. Sci. U. S. A. 107 2010 22002 22007
34. L. Liu Evidence that water can reduce the kinetic stability of protein-hydrophobic ligand interactions J. Am. Chem. Soc. 132 2010 17658 17660
35. R.O. Dror Pathway and mechanism of drug binding to G-protein-coupled receptors Proc. Natl. Acad. Sci. U. S. A. 108 2011 13118 13123
36. P. Schmidtke Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design J. Am. Chem. Soc. 133 2011 18903 18910
37. D. Chandler Interfaces and the driving force of hydrophobic assembly Nature 437 2005 640 647
38. L. Neumann HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature L.C. Kuo, Methods in Enzymology: Fragment-Based Drug Design Tools, Practical Approaches, and Examples Vol. 493 2011 Elsevier 299 320
39. A.M. Giannetti From experimental design to validated hits: a comprehensive walk-through of fragment lead identification using surface plasmon resonance L.C. Kuo, Methods in Enzymology: Fragment-Based Drug Design Tools, Practical Approaches, and Examples Vol. 493 2011 Elsevier 169 218
40. E.C. Hulme, and M.A. Trevethick Ligand binding assays at equilibrium: validation and interpretation Br. J. Pharmacol. 161 2010 1219 1237
41. 2A receptor J. Med. Chem. 54 2011 4312 4323
42. M.J. Carroll Evidence for dynamics in proteins as a mechanism for ligand dissociation Nat. Chem. Biol. 8 2012 246 252
43. V.L. Schramm Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes Ann. Rev. Biophys. 80 2011 703 732
44. R. Neutze, and K. Moffat Time-resolved structural studies at synchrotrons and X-ray free electron lasers: opportunities and challenges Curr. Opin. Struct. Biol. 22 2012 651 659
45. R.O. Dror Exploring atomic resolution physiology on a femtosecond to millisecond timescale using molecular dynamics simulations J. Gen. Phys. 135 2010 555 562
46. I. Buch Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations Proc. Natl. Acad. Sci. U. S. A. 108 2011 10184 10189
47. Y. Shan How does a drug molecule find its target binding site? J. Am. Chem. Soc. 133 2011 9181 9183
48. C.E. Chang Binding pathways of ligands to HIV-1 protease: coarse-grained and atomistic simulations Chem. Biol. Drug Des. 69 2007 5 13
49. X. Li TIGER2: an improved algorithm for temperature intervals with global exchange of replicas J. Chem. Phys. 130 2009 174106
50. M. Kang Gating and intermolecular interactions in ligand-protein association: coarse-grained modeling of HIV-1 protease J. Chem. Theory Comput. 7 2011 3438 3446
51. P. Carlsson Unbinding of retinoic acid from the retinoic acid receptor by random expulsion molecular dynamics Biophys. J. 91 2006 3151 3161
52. 2-adrenergic receptor J. Mol. Biol. 392 2009 1102 1115
53. F. Pietrucci Substrate binding mechanism of HIV-1 protease from explicit-solvent atomistic simulations J. Am. Chem. Soc. 131 2009 11811 11818
54. F. Colizzi Single-molecule pulling simulation can discern active from inactive enzyme inhibitors J. Am. Chem. Soc. 132 2010 7361 7371
55. V. Limongelli Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition Proc. Natl. Acad. Sci. U. S. A. 107 2010 5411 5416
56. C.F. Shuman Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data J. Med. Chem. 47 2004 5953 5961
57. K. Andersson, and M.D. Hamalainen Replacing affinity with binding kinetics in QSAR studies resolves otherwise confounded effects J. Chemometr. 20 2007 370 375
58. T.L. Hill Effect of rotation on the diffusion-controlled rate of ligand-protein association Proc. Natl. Acad. Sci. U. S. A. 72 1975 4918 4922
59. R.A. Copeland Conformational adaptation in drug-target interactions and residence time Future Med. Chem. 3 2011 1491 1501